Triodos Investment Management BV Cuts Stock Position in Edwards Lifesciences Corp (NYSE:EW)

Triodos Investment Management BV lessened its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 26.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,400 shares of the medical research company’s stock after selling 28,600 shares during the period. Edwards Lifesciences makes up 4.5% of Triodos Investment Management BV’s portfolio, making the stock its 7th biggest position. Triodos Investment Management BV’s holdings in Edwards Lifesciences were worth $17,901,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in EW. Nuveen Asset Management LLC raised its position in Edwards Lifesciences by 8,278.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock valued at $730,013,000 after buying an additional 3,904,405 shares during the last quarter. Bessemer Group Inc. increased its position in shares of Edwards Lifesciences by 56,300.0% during the 2nd quarter. Bessemer Group Inc. now owns 503,652 shares of the medical research company’s stock worth $93,045,000 after purchasing an additional 502,759 shares during the last quarter. Marshall Wace North America L.P. increased its position in shares of Edwards Lifesciences by 394.9% during the 2nd quarter. Marshall Wace North America L.P. now owns 364,492 shares of the medical research company’s stock worth $67,336,000 after purchasing an additional 290,838 shares during the last quarter. Jennison Associates LLC increased its position in shares of Edwards Lifesciences by 4.8% during the 2nd quarter. Jennison Associates LLC now owns 6,039,006 shares of the medical research company’s stock worth $1,115,646,000 after purchasing an additional 275,182 shares during the last quarter. Finally, Thoroughbred Financial Services LLC increased its position in shares of Edwards Lifesciences by 20,429.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 267,503 shares of the medical research company’s stock worth $26,750,000 after purchasing an additional 266,200 shares during the last quarter. Institutional investors and hedge funds own 81.31% of the company’s stock.

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 2,500 shares of the company’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $216.71, for a total value of $541,775.00. Following the completion of the transaction, the vice president now owns 20,138 shares of the company’s stock, valued at approximately $4,364,105.98. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Catherine M. Szyman sold 372 shares of the company’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $214.53, for a total value of $79,805.16. Following the completion of the transaction, the vice president now directly owns 18,010 shares of the company’s stock, valued at approximately $3,863,685.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 146,103 shares of company stock valued at $32,806,079. 1.63% of the stock is owned by corporate insiders.

Shares of NYSE:EW traded down $0.99 during trading on Friday, reaching $234.16. 813,724 shares of the company traded hands, compared to its average volume of 1,239,245. The company’s 50 day moving average is $226.79 and its two-hundred day moving average is $203.32. The firm has a market capitalization of $48.47 billion, a PE ratio of 49.82, a PEG ratio of 2.81 and a beta of 0.82. The company has a quick ratio of 2.74, a current ratio of 3.53 and a debt-to-equity ratio of 0.17. Edwards Lifesciences Corp has a 52 week low of $139.64 and a 52 week high of $241.82.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.19. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. Edwards Lifesciences had a return on equity of 32.28% and a net margin of 18.64%. The company’s revenue was up 20.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.07 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corp will post 5.6 EPS for the current year.

EW has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $190.00 to $225.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Cowen boosted their target price on Edwards Lifesciences from $250.00 to $265.00 and gave the stock a “positive” rating in a report on Thursday, October 24th. Stifel Nicolaus boosted their target price on Edwards Lifesciences from $215.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. ValuEngine lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Wells Fargo & Co boosted their target price on Edwards Lifesciences from $250.00 to $262.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the stock. Edwards Lifesciences presently has a consensus rating of “Buy” and a consensus target price of $237.89.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: How are the companies in the S&P 500 selected?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply